Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 2, 2025
CompletedFirst Posted
Study publicly available on registry
October 20, 2025
CompletedOctober 20, 2025
October 1, 2025
October 2, 2025
October 14, 2025
Conditions
Interventions
A dose of 4-7 millicurie (mCi) +/- 10% of radiotracer 18F-Fluorocholine (FCH) manufactured at UCSF will be given intravenously.
A scan is a procedure that produces images of organs and tissues used in conjunction with a radiotracer.
Eligibility Criteria
You may qualify if:
- Age ≥ 13 years.
- Evidence of primary hyperparathyroidism.
- Ability to understand a written informed consent document, and the willingness to sign it.
You may not qualify if:
- \. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Thomas Hopelead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas Hope, MD
University of California, San Francisco
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 2, 2025
First Posted
October 20, 2025
Last Updated
October 20, 2025
Record last verified: 2025-10